Capricor Therapeutics Stock Discussion

$Capricor Therapeutics(CAPR.US)$ Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing

$Capricor Therapeutics(CAPR.US)$
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...

$Capricor Therapeutics(CAPR.US)$ Capricor Therapeutics Inc - Remain on Track to Announce Topline Results From Phase 3 Hope-3 Pivotal Trial in Q4 of 2024

$Capricor Therapeutics(CAPR.US)$ Reuters· just
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy

$United Therapeutics(UTHR.US)$  Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$  Phase 3
$Liquidia(LQDA.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$MorphoSys(MOR.US)$  Phase 3
$Immunocore(IMCR.US)$  Phase 3
$Crinetics(CRNX.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$Capricor Therapeutics(CAPR.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3...

$Capricor Therapeutics(CAPR.US)$ Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy

$Capricor Therapeutics(CAPR.US)$ Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE

$Capricor Therapeutics(CAPR.US)$ we'll. see $5.34 soon.